NCT00056693View on ClinicalTrials.gov

Treatment With SU11248 in Patients With Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Sunitinib

Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity

Trial Locations (11)

19111

Pfizer Investigational Site, Philadelphia

35233

Pfizer Investigational Site, Birmingham

35294

Pfizer Investigational Site, Birmingham

62274

Pfizer Investigational Site, Pinckneyville

63110

Pfizer Investigational Site, St Louis

90033

Pfizer Investigational Site, Los Angeles

90033-0800

Pfizer Investigational Site, Los Angeles

94115-1705

Pfizer Investigational Site, San Francisco

02114

Pfizer Investigational Site, Boston

02115

Pfizer Investigational Site, Boston

02215

Pfizer Investigational Site, Boston

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY